Viridian Therapeutics, Inc. (VRDN) Stock Price & How to Invest
Last updated November 2026
Short answer
VRDN is Viridian Therapeutics, a commercial-stage biotech whose first product, Lumvoa (veligrotug) for thyroid eye disease, won FDA approval in June 2026 and brought in ~$24.7 million of net product revenue in its first full quarter. Investing in it is a bet on a fresh drug launch challenging Amgen's entrenched Tepezza, so the story is execution and market share rather than established profits. As of November 20, 2026 the shares closed near $30.65, up about 37% in a month and roughly flat for the year.
VRDN stock price
As of 2026-11-20, Viridian Therapeutics, Inc. (VRDN) last closed at $29.96, down 1.3% over the past year. Over the past 52 weeks it has traded between $13.30 and $33.78.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Viridian Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
VRDN key stats
At $29.96 on November 20, 2026, Viridian Therapeutics, Inc. (VRDN) has a market cap of $3.4B.
- Market cap
- $3.4B
- Price to book
- 7.0
- Beta
- 1.07
Market cap, P/E and yield are measured at the $29.96 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Viridian Therapeutics, Inc. (VRDN)?
The last two weeks for Viridian Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- VRDN closed at $29.96 on November 20, 2026, down 2.9% over the past five trading days (from $30.87).
- On November 9, 2026, Viridian Therapeutics, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) and other events (Item 7.01, Item 8.01). Read the 8-K on sec.gov
- On November 19, 2026, B of A Securities started coverage at Buy, target $47.00.
- On November 10, 2026, Wedbush raised its target to $44.00 from $42.00 (Outperform).
- On November 10, 2026, Wells Fargo raised its target to $39.00 from $34.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Viridian Therapeutics, Inc. (VRDN) do?
Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double vision (diplopia). Its lead drug, Lumvoa (veligrotug-vvze), is an intravenous anti-IGF-1R antibody that the FDA approved in June 2026 for both active and chronic TED, based on the THRIVE and THRIVE-2 phase 3 trials. The company is also developing subcutaneous elegrobart (an autoinjector TED candidate with positive REVEAL-1 and REVEAL-2 phase 3 data and a BLA filing on track for the first quarter of 2027) and an earlier-stage FcRn portfolio (VRDN-006 and VRDN-008).
The investment picture is that of a newly commercial biotech transitioning from clinical development to a product launch. Trailing revenue is small (~$26 million) because Lumvoa only reached the market in June, and the company runs large quarterly net losses funding R&D and commercial buildout. What supports the story is a strong balance sheet (just over $955 million of cash and investments as of September 30, 2026, against ~$245 million of debt, which management says funds current plans through profitability), a ~$3.5 billion market cap relative to revenue that reflects future-sales expectations, and a differentiated label covering both active and chronic disease. The central question is whether Lumvoa can win share from Amgen's Tepezza, the only prior therapy, before elegrobart and competing subcutaneous formulations reshape the market.
The first full quarter changed the tone. Q2 2026, the quarter that included approval, brought only ~$0.3 million of revenue, but Q3, reported November 4, produced ~$24.7 million of Lumvoa net product revenue against a consensus near $4.7 million, with more than 100 patients treated by September 30 and a net loss of ~$101 million (EPS of -$0.81 versus -$1.02 expected). On November 9 Viridian reported phase 1 data for VRDN-008 showing a 74% peak IgG reduction and a profile supporting every-eight-week dosing, and on November 19 Bank of America started coverage at Buy with a $47 target. As of November 20, 2026 the shares closed near $30.65, roughly flat year to date (-0.1%) and up ~4% over one year, after a ~37% gain over the past month.
What's driving Viridian Therapeutics, Inc. (VRDN)?
1. Lumvoa launch and TED market share
Lumvoa is Viridian's first commercial product and its near-term value driver. In its phase 3 trials it delivered a 70% proptosis responder rate in active TED and 56% in chronic TED versus single-digit placebo rates, and it is the first therapy labeled at approval for both active and chronic stages. How fast it converts that data into prescriptions against Amgen's established Tepezza is the key swing factor. The first full quarter beat expectations by a wide margin: ~$24.7 million of net product revenue, which management attributed to patient demand rather than stocking, with more than 100 patients treated and most starting late in the quarter. Payer policies covered about 30% of lives by early November, mostly at parity with Tepezza, and a permanent J-code takes effect January 1, 2027. Management gave no formal guidance and called it too soon to confirm a sustained trend; analyst models now put full-year 2026 revenue near ~$76 million and 2027 near ~$323 million.
2. Subcutaneous elegrobart pipeline
Elegrobart is Viridian's follow-on TED candidate with positive REVEAL-1 and REVEAL-2 phase 3 topline data and a BLA submission on track for the first quarter of 2027, to be launched by the same commercial team if approved. If it becomes an approved subcutaneous autoinjector option, it could broaden the franchise beyond the intravenous Lumvoa and address patient convenience, a dimension where competitors are also racing to develop under-the-skin formulations.
3. FcRn portfolio and pipeline expansion
Beyond TED, Viridian is advancing an FcRn-targeted portfolio (VRDN-006 and VRDN-008) into autoimmune indications, In November 2026 VRDN-008 phase 1 data in healthy volunteers showed a 74% peak IgG reduction sustained through eight weeks, a 15-18 day half-life and no serious adverse events, and Viridian plans a registrational trial in myasthenia gravis starting in mid-2027, pending regulatory feedback. This gives the company a second therapeutic area to diversify away from single-product concentration, though these programs are early and unproven.
4. Strong cash runway
With just over $955 million in cash and investments as of September 30, 2026 (down from ~$982 million in June) against ~$245 million of debt, and management saying that funds current plans through profitability, Viridian has funding to support the Lumvoa launch and advance its pipeline. That balance sheet reduces near-term financing pressure, although continued large operating losses and potential future raises remain part of the picture for a company still building revenue.
What are the risks to Viridian Therapeutics, Inc. (VRDN)?
Viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders. The stock has already shown that sensitivity, trading in a 52-week range of roughly $13 to $34 and gaining ~37% in the single month after the Q3 report, which raises the bar for the next quarters. Broad payer coverage is only targeted six to nine months after launch, and management has said it is too early to confirm a sustained trend.
What is the Viridian Therapeutics, Inc. (VRDN) forecast?
17 analysts publish price targets on VRDN, averaging $42.76 as of November 2026, or +42.7% against the $29.96 share price on November 20, 2026. The published targets run from $33.00 to $54.00, a moderate spread, and the ratings split 18 buy, 0 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full VRDN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is VRDN a buy or a sell?
We give no verdict on Viridian Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Lumvoa launch and TED market share. Lumvoa is Viridian's first commercial product and its near-term value driver. The most optimistic published target, $54.00, assumes this works close to its best case.
The case against. Viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized. The most pessimistic target, $33.00, is roughly what VRDN is worth if this bites instead.
Read the full bull and bear case on VRDN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Viridian Therapeutics, Inc. (VRDN) split its stock?
Yes. Viridian Therapeutics, Inc. (VRDN) has had 2 share splits in the last 10 years:
- 1:15 on November 7, 2016, so every share held became 0.06666666666666667 shares.
- 1:15 on November 13, 2020, so every share held became 0.06666666666666667 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of VRDN the day before the 1:15 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Viridian Therapeutics, Inc. (VRDN) valued?
Market cap, P/E and dividend yield at today's price are in the VRDN key stats above. The business figures below come from Viridian Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$26M, almost all Lumvoa sales in Q3 2026
- Lumvoa net product revenue (Q3 2026): ~$24.7M vs ~$4.7M consensus revenue
- Net loss (TTM): ~$398M; Q3 2026 ~$101M
- Cash and investments: ~$955M (Sep 2026), debt ~$245M
- Dividend: None
As of November 2026: As of November 20, 2026, Viridian carried a roughly $3.5 billion market cap against ~$26 million of trailing revenue, nearly all of it from Lumvoa's first full quarter, so the ~132x price-to-sales figure says little about the launch. The valuation rests on expectations for TED sales (consensus ~$50 million in Q4 2026 and ~$323 million in 2027) and on a cash balance near $955 million that funds continuing losses.
Who competes with Viridian Therapeutics, Inc. (VRDN)?
Thyroid eye disease incumbents
Amgen's Tepezza (teprotumumab) was the only approved TED therapy before Lumvoa and is the direct competitor Viridian must take share from. Amgen is also advancing a subcutaneous Tepezza formulation, so the incumbent is actively defending and extending its franchise.
IGF-1R and next-generation TED developers
Other biopharma companies pursuing IGF-1R antibodies and alternative mechanisms for thyroid eye disease, including subcutaneous and oral candidates, compete for the same rare-disease patient population that both Lumvoa and Viridian's own elegrobart target.
Rare-disease and autoimmune biotechs
Broader clinical-stage and commercial rare-disease biotechs, including those developing FcRn-targeted therapies in autoimmune indications, compete with Viridian's FcRn portfolio for investor capital, clinical talent, and eventual market positioning.
What stocks are similar to Viridian Therapeutics, Inc. (VRDN)?
Other names that sit close to VRDN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Viridian Therapeutics, Inc. (VRDN)
There are three common ways to get VRDN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VRDN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where VRDN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Viridian Therapeutics, Inc. (VRDN)
VRDN is an early-launch biotech story where the thesis rides on how quickly Lumvoa can take thyroid-eye-disease share from Tepezza, funded by a deep cash balance but not yet by meaningful revenue. A first full quarter of sales far above consensus, positive VRDN-008 data and new Buy coverage lifted the stock about 37% in the month to November 20, 2026, so the next few quarters of prescriptions now carry higher expectations.
More on Viridian Therapeutics, Inc. (VRDN)
Whether VRDN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VRDN a buy or a sell?, and where the stock could go from here in the VRDN stock forecast.
For income investors, whether VRDN pays a dividend and how the payout looks is covered in does VRDN pay a dividend? And to weigh VRDN against a peer, read the full side-by-side comparisons: VRDN vs AMGN and VRDN vs MRNA.
Wondering how VRDN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Viridian Therapeutics, Inc.
Ask Walnut's AI anything about VRDN and see how it fits what you own.
FAQ
What does Viridian Therapeutics do?
+
Viridian is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging and double vision. Its lead drug, Lumvoa (veligrotug), won FDA approval in June 2026, and it is developing additional TED and autoimmune candidates.
What is Lumvoa (veligrotug)?
+
Lumvoa is Viridian's first commercial product, an intravenous anti-IGF-1R antibody approved in June 2026 for both active and chronic thyroid eye disease. In phase 3 trials it produced proptosis responder rates of roughly 70% in active and 56% in chronic disease versus single-digit placebo rates.
Is VRDN profitable?
+
No. In Q3 2026, its first full quarter of Lumvoa sales, Viridian reported ~$25.8 million of revenue and a net loss near $101 million, after a ~$127 million loss in Q2 and a ~$105 million loss in Q1 driven by roughly $78 million of R&D and $39 million of SG&A spending. The trailing twelve-month net loss is ~$398 million. It is a pre-profit biotech funding a new drug launch, though management says its cash funds current plans through profitability.
How much cash does Viridian have?
+
Viridian reported just over $955 million of cash, cash equivalents and marketable securities as of September 30, 2026, down from ~$982 million at June 30, with about $245 million of debt. Management says that balance funds its current plans through profitability, including the Lumvoa launch and the pipeline, though the company continues to run large operating losses.
Who competes with Viridian?
+
The main competitor is Amgen's Tepezza, the only prior approved thyroid eye disease therapy, which is also developing a subcutaneous version. Other IGF-1R and next-generation TED developers and rare-disease biotechs also compete for the same patient population.
What is elegrobart?
+
Elegrobart is Viridian's follow-on thyroid eye disease candidate, a subcutaneous autoinjector therapy with positive REVEAL-1 and REVEAL-2 phase 3 topline data. The company says a BLA submission is on track for the first quarter of 2027, aiming to offer a more convenient administration option than intravenous Lumvoa.
Why is VRDN's market cap so high relative to revenue?
+
Viridian carried roughly a $3.5 billion market cap as of November 20, 2026 (about 132 times trailing sales) on only ~$26 million of trailing revenue, because Lumvoa launched in June and has just one full quarter of sales. The valuation reflects investor expectations for future thyroid-eye-disease sales rather than current earnings, which is common for newly commercial biotechs.
What are the main risks for VRDN?
+
Key risks include an unproven commercial launch against entrenched Tepezza, heavy concentration in a single rare-disease market, ongoing losses that could require future capital, and clinical or regulatory setbacks in its pipeline. Walnut is not an investment adviser, so treat this as descriptive context, not a recommendation.
How did Viridian do in its latest quarter?
+
In Q3 2026, reported November 4 and the first full quarter of Lumvoa sales, Viridian booked ~$24.7 million of net product revenue against a consensus near $4.7 million, with more than 100 patients treated by September 30. The net loss was ~$101 million and EPS of -$0.81 beat the -$1.02 consensus. Cash ended near $955 million. Consensus for Q4 sits near $50 million of revenue and -$0.72 of EPS.
How has VRDN stock performed in 2026?
+
As of November 20, 2026, VRDN closed near $30.65, roughly flat year to date (-0.1%) and up ~4% over one year, within a 52-week range of roughly $13 to $34. Most of the recovery came in the past month, a ~37% gain after the Q3 launch numbers, the VRDN-008 data and new Bank of America coverage. The 17 analysts tracked by Yahoo Finance have a mean price target near $43. Walnut is not an investment adviser, so these figures are descriptive context rather than a forecast.
What did the VRDN-008 phase 1 data show?
+
On November 9, 2026 Viridian reported that VRDN-008, its FcRn-targeted antibody, cut IgG by 74% at peak in healthy volunteers, with the reduction sustained through eight weeks after subcutaneous dosing and a half-life of 15-18 days. The company said the profile spared albumin and LDL, with no serious adverse events, and supports potential every-eight-week dosing. It plans a registrational myasthenia gravis trial starting mid-2027, pending regulatory feedback.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Viridian Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.